Q1 2026 ARS Pharmaceuticals Inc Earnings Call Transcript
Key Points
- ARS Pharmaceuticals Inc (SPRY) reported a strong start to 2026 with $22.7 million in total revenue, including $17.5 million in US net product revenue for neffy.
- The company achieved three times the volume of neffy prescriptions year-over-year and more than doubled the revenue.
- Approximately 90% of commercial coverage was achieved, with 57% without prior authorization, improving access for patients.
- The introduction of a $199 retail pharmacy cash option for neffy aims to reduce out-of-pocket costs and improve affordability.
- Health Canada and the European Commission have approved neffy, expanding its market presence internationally.
- The prior authorization process remains a barrier to prescriber adoption, creating friction that can delay or deter prescribing.
- High retail prices for neffy, sometimes exceeding $1,000, have created confusion and impacted prescribing decisions.
- SG&A expenses were high at $72.2 million, reflecting significant commercialization investments.
- The CVS Caremark proposal process has been delayed due to new legislation and ongoing FTC-related interactions.
- The company is still working to achieve unrestricted Medicaid coverage in the majority of states, which is crucial for market expansion.
Good morning, and welcome to ARS Pharmaceuticals' firstquarter 2026 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I will now turn the call over to Justin Chakma, Chief Business Officer. Please go ahead.
Good morning, and thank you for joining our first quarter 2026 earnings conference call. With me on the call are Richard Lowenthal, our Co-Founder, President; and CEO, Eric Karas, our Chief Commercial Officer; and Kathy Scott, our Chief Financial Officer.
Earlier this morning, we issued a press release detailing our financial results and commercial highlights for the first quarter of 2026. Our press release and our slide presentation are available in the Investors & Media section of our website.
Before we begin, please note that today's remarks may contain forward-looking statements. Actual results may differ materially. Please refer to our press release and SEC filings for further risk disclosures.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
